

United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/165,546	10/02/1998	KNUTH ALEXANDER	LUD5466.4-JE	8012	
24972	7590 09/02/2003				
	T & JAWORSKI, LLP		EXAM	NER	
666 FIFTH A NEW YORK	NY 10103-3198		VANDERVEGT, FRANCOIS P		
			ART UNIT	PAPER NUMBER	
			1644	< 0	
			DATE MAILED: 09/02/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Tedemark Office

Address: COMMISSION OR PATENTS

P.O. Box 1450 Alexandria, Virginia 22313-1450

09/165,546

APPLICATION NO./
CONTROL NO.

FILING DATE
FIRST NAMED INVENTOR /
PATENT IN REEXAMINATION

ATTORNEY DOCKET NO.

EXAMINER	

ART UNIT PAPER

50

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The Examiner in charge of your application in the USPTO has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to F. Pierre VanderVegt, Ph.D. in Art Unit 1644.

The response to the Ex parte Quayle action filed on June 6, 2003 is not fully responsive to the prior Office action because:

The computer readable form of the sequence listing is defective for the reasons stated on the enclosed Notice to Comply and marked-up copy of the Raw Sequence Listing. Applicant must submit a substitute CRF and paper copy of the sequence listing, as well as a statement that the content of the paper copy and the CRF are the same.

Since the submission appears to be a bona fide attempt to provide a complete reply to the prior Office action, applicant is given a shortened statutory period of ONE MONTH or THIRTY DAYS from the mailing date of this letter, whichever is longer, to submit a complete reply. This shortened statutory period supersedes the time period set in the prior Office action. This time period may be extended pursuant to 37 CFR 1.136(a).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to F. Pierre VanderVegt whose telephone number is (703) 305-4441. The examiner can normally be reached on M-Th 6:30-4:00; Alternate Fridays 6:30-3:00. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (703) 308-3973. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center number is (703) 305-3014. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

F. Pierre VanderVegt, Ph.D. Patent Examiner

August 28, 2003

PHILLIP GAMBEL, PH.D
PRIMARY EXAMINER
THE CONTROLLOGO
8/21/60

Application No.: 09/165 546

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

X	1	This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2	. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3	. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4	. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5	The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	e	3. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	7	7. Other:
Аp	p	licant Must Provide:
X	•	Ap rinitiat of substitute computer readable form (CRF) copy of the "Sequence Listing".
X	i	Ap initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	•	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
~ _		avections regarding compliance to these requirements, please contact.

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216


For CRF Submission Help, call (703) 308-4212

For Patentin software help, call (703) 308-6856

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

RAW SEQUENCE LISTING.

ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09//65,546 Source: 1600 Date Processed by STIC: 09//65,546 09//65,546 09//65,546 Date Processed by STIC:

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- 3. Hand Carry directly to:

U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202

Or


U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 04/24/2003

ERROR DETECTED	SUGGESTED CORRECTION	SERIAL NUMBER: 69//05 546 B
attn: new rules case	s: Please disregard english "	alpha" headers, which were inserted by Pto Software
1Wrapped Nucleics Wrapped Aminos		"wrapped" down to the next line. This may occur if your file creating it. Please adjust your right margin to .3; this will
2Invalid Line Length	The rules require that a line not exceed	72 characters in length. This includes white spaces.
3 Misaligned Amino Numbering	The numbering under each 5th amino actuse apace characters, instead.	id is misaligned. Do not use tab codes between numbers;
4Non-ASCII	The submitted file was not saved in AS ensure your subsequent submission is	CII(DOS) text, as required by the Sequence Rules. Please saved in ASCII text.
5Variable Length	each n or Xaa can only represent a sl	presenting more than one residue. Per Sequence Rules, ngle residue. Please present the maximum number of each cate in the <220>-<223> section that some may be missing.
6Patentin 2.0 "bug"	previously coded nucleic acid sequence	red the <220>-<223> section to be missing from amino acid PatentIn would automatically generate this section from the Please manually copy the relevant <220>-<223> section to This applies to the mandatory <220>-<223> sections for
7Skipped Sequences (OLD RULES)	(2) INFORMATION FOR SEQ ID NO: (i) SEQUENCE CHARACTES	nal, please insert the following lines for each skipped sequence: X: (insert SEQ ID NO where "X" is shown) USTICS: (Do not insert any subheadings under this heading) ID NO:X: (insert SEQ ID NO where "X" is shown)
	Please also adjust the "(ii) NUMBER O	F SEQUENCES:" response to Include the skipped sequences.
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If Intenti <210> sequence id number <400> sequence id number 000	onal, please insert the following lines for each skipped sequence.
Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected Per 1.823 of Sequence Rules, use of <22 In <220> to <223> section, please explain	ted in the Sequence Listing. 10>-<223> is MANDATORY if n's or Xaa's are present. in location of n or Xaa, and which residue n or Xaa represents.
0Invalid <213> Response	Per 1.823 of Sequence Rules, the only vescientific name (Genus/species). <220> is Artificial Sequence	alld <213> responses are: Unknown, Artificial Sequence, or -<223> acction is required when <213> response is Unknown or
1Use of <220>	Use of <220> to <223> is MANDATOR "Unknown." Please explain source of ge	> "Feature" and associated numeric identifiers and responses. Y if <213> "Organism" response is "Artificial Sequence" or metic material in <220> to <223> section. L 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
2PatentIn 2.0 "bug"	resulting in missing mandatory numeric	on of Patentin version 2.0. This causes a corrupted file, identifiers and responses (as indicated on raw sequence or any other manual means to copy file to floppy disk.
3Misuso of n	n can only be used to represent a single t any value not specifically a nucleotide.	ancleotide in a nucleic acid sequence. N is not used to represent

AMC/MH - Biotechnology Systems Branch - 08/21/2001



1600

RAW SEQUENCE LISTING

DATE: 08/28/2003

PATENT APPLICATION: US/09/165,546C

TIME: 09:59:47

Input Set : A:\pto.da.txt

Output Set: N:\CRF4\08282003\I165546C.raw

SEQUENCE LISTING

	_		SEQUENCE LISTING
	1	(1) GENE	RAL INFORMATION:
C>	2	(i)	APPLICANT: Knuth, Alexader; Jager, Elke; Chen, Yao,
	3		Canlan, Matt; Gure, Ali, Old, Lloyd, Ritter, Gerd
	5	(ii)	TITLE OF INVENTION: ISOLATED PEPTIDES CORRESPONDING TO
	6		AMINO ACID SEQUENCES OF NY-ESO-1, WHICH BIND TO
	7		MHC CLASS I AND MHC CLASS II MOLECULES, AND
	8		USES THEREOF
	10	(iii)	NUMBER OF SEQUENCES: 15
	12	(iv)	CORRESPONDENCE ADDRESS:
	13		(A) ADDRESSEE: FULBRIGHT & JAWORSKI LLP
	14		(B) STREET: 666 Fifth Avenue
	15		(C) CITY: New York City
	16		(D) STATE: New York ON COUNTRY, UCA
	17		CELUDUNIRI: USA
	18		(F) ZIP: 10158
	20	(V)	COMPUTER READABLE FORM:
	21		(A) MEDIUM TYPE: Diskette, 3.5 inch, 144 kb storage
	22		(B) COMPUTER: IBM
	23		(C) OPERATING SYSTEM: PC-DOS
	24		(D) SOFTWARE: WordPerfect
	26	(Vi)	CURRENT APPLICATION DATA:
C>			(A) APPLICATION NUMBER: US/09/165,546C
C>	28		(B) FILING DATE: 10-Feb-1998
	29		(C) CLASSIFICATION: 530
	39	(vii)	(C) CLASSIFICATION: 530 PRIOR APPLICATION NUMBER: 08/937,269 (B) FILING DATE: April 17, 1998 (A) APPLICATION NUMBER: 08/037,263 (B) APPLICATION NUMBER: 08/037,263
	32		(A) APPLICATION NUMBER: 08/937,263
	33		(B) FILING DATE: April 17, 1998 $\int delet = \frac{3}{4} \frac{1000}{1000}$
	36		(A) APPLICATION NUMBER: 00/93/,203
	37		
	40		(A) APPLICATION NUMBER: US 08/752,182
	41		(B) FILING DATE: 03-October-1996
	43	(Viii)	ATTORNEY/AGENT INFORMATION:
·	44		(A) NAME: Hanson, Norman D.
	45		(B) REGISTRATION NUMBER: 30,946
	46		(C) REFERENCE/DOCKET NUMBER: LUD 5466.3
	48	(1X)	TELECOMMUNICATION INFORMATION:
	49		(A) TELEPHONE: (212) 688-9200
	50		(B) TELEFAX: (212) 838-3884

ERRORED SEQUENCES

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/165,546C TIME: 09:59:47

Input Set: A:\pto.da.txt
Output Set: N:\CRF4\08282003\I165546C.faw

```
130 (2) INFORMATION FOR SEQ ID NO: 3:
     131
              (i) SEQUENCE CHARACTERISTICS:
                   (B) TYPE: (nuclear acid) rucleic avid This is a global Essor
(C) STRANDEDNESS: single
                   (A) LENGTH: 32 base pairs
     132
E--> 133
     134
     135
                   (D) TOPOLOGY: linear
     136
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
     138 CACACAAAGC TTGGCTTAGC GCCTCTGCCC TG
     274 (2) INFORMATION FOR SEQ ID NO: 15:
     275
              (i) SEQUENCE CHARACTERISTICS:
     276
                   (A) LENGTH: 180 amino acids
     277
                   (B) TYPE: amino acid
     278
                   (D) TOPOLOGY: linear
     279
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15
                                                                15 Ala misaligned nos.
     281 Met Gln Ala Glu Gly Arg Gly Thr Gly Gly Ser Thr Gly Asp Ala
E--> 282
                                                                          do not use TAB.

alid codes belivées

rumber
     283 Asp Gly Pro Gly Gly Pro Gly Ile Pro Asp Gly Pro Gly Gly Asn
     284
E--> 285 Ala Gly Gly Pro Gly Glu Ala Gly Ala Thr Gly Gly Arg (Aly) Pro
     286
     287 Arg Gly Ala Gly Ala Ala Arg Ala Ser Gly Pro Gly Gly Gly Ala
     288
     289 Pro Arg Gly Pro His Gly Gly Ala Ala Ser Gly Leu Asn Gly Cys
     290
     291 Cys Arg Cys Gly Ala Arg Gly Pro Glu Ser Arg Leu Leu Glu Phe
     292
     293 Tyr Leu Ala Met Pro Phe Ala Thr Pro Met Glu Ala Glu Leu Ala
     294
                                              100
                                                                   105
     295 Arg Arg Ser Leu Ala Gln Asp Ala Pro Pro Leu Pro Val Pro Gly
     296
                         110
                                              115
                                                                   120
     297 Val Leu Leu Lys Glu Phe Thr Val Ser Gly Asn Ile Leu Thr Ile
     298
                         125
                                                                   135
                                              130
     299 Arg Leu Thr Ala Ala Asp His Arg Gln Leu Gln Leu Ser Ile Ser
     300
                         140
                                              145
                                                                   150
     301 Ser Cys Leu Gln Gln Leu Ser Leu Leu Met Trp Ile Thr Gln Cys
     302
                         155
                                              160
                                                                   165
     303 Phe Leu Pro Val Phe Leu Ala Gln Pro Pro Ser Gly Gln Arg Arg
     304
                         170
                                              175
                                                                   180
     306 25303395_1.DOC -1-
```

VERIFICATION SUMMARY

DATE: 08/28/2003

PATENT APPLICATION: US/09/165, 546C - TIME: 09:59:48

Input Set : A:\pto.da.txt

Output Set: N:\CRF4\08282003\I165546C.faw

```
L:2 M:220 C: Keyword misspelled or invalid format, [(i) APPLICANT:]
L:27 M:220 C: Keyword misspelled or invalid format, [(A) APPLICATION NUMBER:]
L:28 M:220 C: Keyword misspelled or invalid format, [(B) FILING DATE:]
L:66 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:70 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:73 M:334 W: (2) Invalid Amino Acid in Coding Region, NUMBER OF INVALID KEYS:1
L:74 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:78 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:82 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:86 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:90 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:94 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:98 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:102 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:106 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:110 M:336 W: Invalid Amino Acid Number in Coding Region, SEQ ID:1
L:132 M:241 E: Invalid Alpha Header Field, [TYPE:], SeqNo=3
L:188 M:220 C: Keyword misspelled or invalid format, [(i) SEQUENCE CHARACTERISTICS:]
L:282 M:332 E: (32) Invalid/Missing Amino Acid Numbering, SEQ ID:15
L:285 M:330 E: (2) Invalid Amino Acid Designator, 1
```